Charlene Sanders
Acute Care · Louisville, KYNPI 1417689324
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,584 and has fallen 82.0% since, to $285 in 2025. Among acute care clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$851
- Novartis$622
- Merck$354
- Amgen$348
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$243
- Irhythm Technologies, Inc.$198
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,625100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $851 |
| Novartis | 51 | $622 |
| Merck | 16 | $354 |
| Amgen | 21 | $348 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $243 |
| Irhythm Technologies, Inc. | 5 | $198 |
| Pfizer | 9 | $182 |
| Bayer | 2 | $142 |
| Novo Nordisk | 4 | $123 |
| Sanofi-aventis U.S. LLC | 5 | $93 |
| Boston Scientific | 4 | $69 |
| Alnylam Pharmaceuticals Inc. | 4 | $69 |
| Teleflex LLC | 1 | $67 |
| Johnson & Johnson | 3 | $45 |
| Edwards Lifesciences | 1 | $42 |
| Abiomed | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Heartflow, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Abbott | 1 | $16 |
| Impulse Dynamics (USA) Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$219
- LOKELMA$125
- Kerendia$125
- FARXIGA$124
- ZIO XT Patch$115
- Zio monitor$115
- LifeVest$108
- BRILINTA$106
How this compares
$3,625 in reported general payments places this provider in the 90th percentile of 319 acute care providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 310 | $254,783 |
| EntrestoSacubitril/Valsartan | 116 | $93,248 |
| FarxigaDapagliflozin Propanediol | 71 | $45,764 |
| XareltoRivaroxaban | 34 | $41,823 |
| BrilintaTicagrelor | 57 | $38,350 |
| Repatha SureclickEvolocumab | 30 | $25,273 |
| JardianceEmpagliflozin | 14 | $17,765 |
| MultaqDronedarone Hcl | 14 | $11,078 |
| OzempicSemaglutide | 12 | $10,600 |
| Praluent PenAlirocumab | 17 | $9,453 |
| DapagliflozinDapagliflozin Propanediol | 16 | $7,735 |
| Prasugrel Hcl | 49 | $4,672 |
| Metoprolol Succinate | 465 | $4,660 |
| Midodrine Hcl | 45 | $3,455 |
| Ranolazine ErRanolazine | 39 | $2,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $182 | $254,783310 claims |
| NovartisEntresto | $622 | $93,248116 claims |
| AstraZenecaFarxiga, Brilinta | $851 | $84,114128 claims |
| Johnson & JohnsonXarelto | $45 | $41,82334 claims |
| Boehringer IngelheimJardiance | $17 | $17,76514 claims |
| Sanofi-aventis U.S. LLCMultaq | $93 | $11,07814 claims |
| Novo NordiskOzempic | $123 | $10,60012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 319 acute care providers in Kentucky.
Other acute care in Louisville
- Jayla GreeneLouisville$5K
- Katherine WittmerLouisville$5K
- Sarah SmithLouisville$4K
- Adam CumminsLouisville$3K
- Kimberly MeyerLouisville$3K
- Nidhi MoreLouisville$3K
- Brian GackenbachLouisville$2K
- Jennifer AustinLouisville$2K
- Donnell ProctorLouisville$2K
- Christina SchipperLouisville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.